The PS externalization pathway as a potential new target for the development of anti-HIV-1 therapies Aug. 7, 2017
Phase III trial shows HIV suppression with bictegravir/emtricitabine/tenofovir coformulation Aug. 2, 2017
MK-8591 shows promise as a novel HIV prophylaxis drug in preclinical and early clinical setting July 27, 2017
Phase III data for glecaprevir/pibrentasvir combination in HIV-1/HCV coinfected patients presented July 26, 2017
RSS